Literature DB >> 8318348

Recurrent malignant glioma: detection with 131I labeled monoclonal antibody G-22, positron emission tomography and magnetic resonance imaging.

M Oshima1, J Yoshida, T Wakabayashi, K Ito, M Tadokoro, T Kato, S Sakuma.   

Abstract

A 45-year-old man with suspected recurrent malignant glioma was evaluated by magnetic resonance imaging (MRI), positron emission tomography (PET) and 131I labeled monoclonal antibody G-22 (G-22) scan. Following Gadolinium-DTPA, a TI-weighted spin echo image (TR 500 msec, TE 20 msec) demonstrated a large mass with an irregular margin in the left temporo-parietal area. An 18F labeled fluorodeoxyglucose PET study demonstrated marked accumulations in the left temporo-parietal area. Serial 131I-G-22 scintigraphy was obtained for a week after the injection. The uptake was most increased on the 2nd day after the injection. 131I G-22 was specific for tumor-associated antigens.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8318348     DOI： 10.1007/bf03164577

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN： 0914-7187            Impact factor:   2.668


  14 in total

1.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.

Authors:  G Di Chiro
Journal:  Invest Radiol       Date:  1987-05       Impact factor: 6.016

Review 2.  Clinical application of PET for the evaluation of brain tumors.

Authors:  R E Coleman; J M Hoffman; M W Hanson; H D Sostman; S C Schold
Journal:  J Nucl Med       Date:  1991-04       Impact factor: 10.057

3.  Radioimaging of human malignant gliomas using indium-labelled monoclonal antibodies.

Authors:  J Bergh; S Nilsson; C Liljedahl; E Maripuu; G Sivolapenko; A Epenetos; D Stavrou
Journal:  Nucl Med Commun       Date:  1990-06       Impact factor: 1.690

Review 4.  Positron emission tomography in the study of human tumors.

Authors:  R P Beaney
Journal:  Semin Nucl Med       Date:  1984-10       Impact factor: 4.446

5.  Radioimaging of human glioma xenografts with 123I labeled monoclonal antibody G-22 against glioma-associated antigen.

Authors:  J Yoshida; M Mizuno; I Inoue; T Wakabayasi; K Sugita; H Seo; K Chiba
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

6.  Cranial postoperative site: assessment with contrast-enhanced MR imaging.

Authors:  A D Elster; D A DiPersio
Journal:  Radiology       Date:  1990-01       Impact factor: 11.105

7.  Brain radiation lesions: MR imaging.

Authors:  G C Dooms; S Hecht; M Brant-Zawadzki; Y Berthiaume; D Norman; T H Newton
Journal:  Radiology       Date:  1986-01       Impact factor: 11.105

8.  Recurrent rectal cancer and scar: differentiation with PET and MR imaging.

Authors:  K Ito; T Kato; M Tadokoro; T Ishiguchi; M Oshima; T Ishigaki; S Sakuma
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

9.  Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study.

Authors:  G Di Chiro; J Hatazawa; D A Katz; H V Rizzoli; D J De Michele
Journal:  Radiology       Date:  1987-08       Impact factor: 11.105

10.  Application of contrast agents in CT and MRI (NMR): their potential in imaging of brain tumors.

Authors:  C Claussen; M Laniado; E Kazner; W Schörner; R Felix
Journal:  Neuroradiology       Date:  1985       Impact factor: 2.804
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.